Epizyme, Inc. (NASDAQ:EPZM) Receives “Buy” Rating from HC Wainwright

Epizyme, Inc. (NASDAQ:EPZM)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued on Monday, August 7th.

Several other research firms have also recently commented on EPZM. Cann reiterated a “buy” rating and set a $26.00 price target on shares of Epizyme in a report on Tuesday, April 25th. BidaskClub upgraded shares of Epizyme from a “strong sell” rating to a “sell” rating in a report on Saturday, August 5th. ValuEngine upgraded shares of Epizyme from a “sell” rating to a “hold” rating in a report on Saturday, June 24th. Oppenheimer Holdings, Inc. set a $26.00 price target on shares of Epizyme and gave the stock a “buy” rating in a report on Monday, June 5th. Finally, Zacks Investment Research upgraded shares of Epizyme from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a report on Wednesday, July 12th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $23.38.

Epizyme (NASDAQ:EPZM) opened at 14.05 on Monday. Epizyme has a 1-year low of $7.02 and a 1-year high of $18.50. The stock’s 50 day moving average is $13.64 and its 200-day moving average is $14.51. The company’s market capitalization is $821.45 million.

Epizyme (NASDAQ:EPZM) last posted its quarterly earnings results on Friday, August 4th. The biopharmaceutical company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.08. Epizyme had a negative net margin of 1,376.33% and a negative return on equity of 63.10%. The company had revenue of $10 million during the quarter, compared to analysts’ expectations of $3.95 million. During the same quarter in the previous year, the business posted ($0.49) EPS. The firm’s revenue was up 2027.7% on a year-over-year basis. On average, analysts expect that Epizyme will post ($2.39) earnings per share for the current fiscal year.

In related news, CFO Andrew E. Singer sold 3,024 shares of the company’s stock in a transaction on Friday, June 30th. The shares were sold at an average price of $15.50, for a total value of $46,872.00. Following the completion of the sale, the chief financial officer now owns 40,529 shares in the company, valued at approximately $628,199.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the company’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $13.44, for a total transaction of $201,600.00. Following the completion of the sale, the insider now owns 22,228 shares of the company’s stock, valued at approximately $298,744.32. The disclosure for this sale can be found here. In the last 90 days, insiders sold 50,524 shares of company stock valued at $746,797. Company insiders own 25.20% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in EPZM. The Manufacturers Life Insurance Company increased its stake in Epizyme by 3.3% in the second quarter. The Manufacturers Life Insurance Company now owns 33,137 shares of the biopharmaceutical company’s stock valued at $501,000 after buying an additional 1,068 shares during the period. State Street Corp increased its stake in Epizyme by 59.6% in the second quarter. State Street Corp now owns 1,764,450 shares of the biopharmaceutical company’s stock valued at $26,644,000 after buying an additional 658,727 shares during the period. Palo Alto Investors LLC increased its stake in Epizyme by 18.9% in the second quarter. Palo Alto Investors LLC now owns 5,698,296 shares of the biopharmaceutical company’s stock valued at $86,044,000 after buying an additional 907,245 shares during the period. Tudor Investment Corp ET AL acquired a new stake in Epizyme during the second quarter valued at approximately $215,000. Finally, Numeric Investors LLC acquired a new stake in Epizyme during the second quarter valued at approximately $376,000. Hedge funds and other institutional investors own 81.24% of the company’s stock.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).